Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05654675 | Evaluation of the Use of the FUR to Quantify Tumor Glucose Consumption in Oncologic PET | recruiting | — | 30 | Academisch Ziekenhuis MaastrichtOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06630611 | Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)(PragmaTIL) | recruiting | Phase 2 | 40 | Vall d'Hebron Institute of Oncology |
| 1 |
| Jan 28, 2025 |
| clinicaltrials |
| NCT06796517 | Immunotherapy in Lymphoma | recruiting | — | 72 | Sung-Soo ParkOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT04324164 | Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC | recruiting | — | 800 | Hunan Province Tumor HospitalOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT05341557 | A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma | recruiting | Phase 1 | 110 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT05504278 | Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation | recruiting | Phase 1 | 144 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06793813 | Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 | 44 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06790797 | Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients | recruiting | — | 50 | Zhao JunOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT06071013 | Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients | recruiting | Phase 1 / Phase 2 | 20 | China Medical University HospitalOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06758557 | A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 282 | Huabo Biopharm Co., Ltd.INDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06788366 | AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer | recruiting | — | 2,000 | IRCCS San RaffaeleOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06786468 | Standard Care With or Without Early Palliative Care Provided by Palliative Care Specialist in Advanced Non-small Cell Lung Cancer Patients | recruiting | N/A | 104 | Mahidol UniversityOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06684418 | Artificial Intelligence-based Model for the Prediction of Occult Lymph Node Metastasis and Improvement of Clinical Decision-making in Non-small Cell Lung Cancer | recruiting | — | 6,000 | Fudan UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06667167 | First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy | recruiting | Phase 2 | 21 | Nir PeledOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06780826 | A Study on the Efficacy of Atezolizumab Combined with Chemotherapy | recruiting | — | 1,430 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06778512 | LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer | recruiting | — | 2,500 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06581419 | A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors | recruiting | Phase 1 / Phase 2 | 78 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06775275 | A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC | recruiting | Phase 2 | 60 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06467383 | A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced(Key-Early) | recruiting | — | 600 | MSD Italia S.r.l.INDUSTRY | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06500312 | Decoding the Association of Imaging and Tumor Microenvironment in Lung Cancer Using Radiogenomic Approach（Radiogenomics-Lung） | recruiting | — | 150 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT00682032 | The Effect of Beta-glucan in Non-Small Cell Lung Cancer | recruiting | N/A | 300 | University of LouisvilleOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06422403 | A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers(VALUE-CHECK) | recruiting | Phase 2 | 360 | National University Hospital, SingaporeOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06768151 | A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer | recruiting | Phase 1 | 48 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06769295 | A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC | recruiting | Phase 2 | 28 | Sichuan UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06769971 | Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC | recruiting | Phase 2 | 80 | Sichuan UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06090266 | A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | recruiting | Phase 1 / Phase 2 | 168 | OncoResponse, Inc.INDUSTRY | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06644066 | Partial Pressure of Oxygen Control Method in Identification of Intersegmental Plane | recruiting | N/A | 60 | Tang-Du HospitalOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06480864 | Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer | recruiting | N/A | 38 | Yunpeng LiuOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06528743 | Feasibility of Primer Shot Radiotherapy for Non-small Cell Lung Cancer - PRIMER(PRIMER) | recruiting | N/A | 34 | The Netherlands Cancer InstituteOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT05417321 | A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 80 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 2 | Jan 3, 2025 | clinicaltrials |
| NCT06756217 | 68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC | recruiting | — | 40 | Ruijin HospitalOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT05681962 | Practice of Oxygenation and Respiratory Support During Fiberoptic Bronchoscopy | recruiting | — | 10,000 | University Magna GraeciaOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06751849 | Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment | recruiting | Phase 2 | 10 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06751901 | Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment | recruiting | Phase 2 | 10 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06752044 | Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment | recruiting | N/A | 10 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06752057 | Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment | recruiting | N/A | 10 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT04675476 | A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening | recruiting | N/A | 368 | Georgetown UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06749691 | Liposomal Irinotecan and Apatinib in ES-SCLC(LIAES) | recruiting | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06749860 | Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression | recruiting | Phase 2 | 58 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06749886 | An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting | recruiting | Phase 2 | 22 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05877430 | Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | recruiting | Phase 1 / Phase 2 | 160 | CJ Bioscience, Inc.INDUSTRY | 2 | Dec 20, 2024 | clinicaltrials |
| NCT06532591 | Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC | recruiting | Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06745830 | Lymph Node Pathologic Grading Strategy | recruiting | — | 2,998 | Fudan UniversityOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06281678 | A Study of IBI363 in Subjects with Advanced Solid Malignancies | recruiting | Phase 2 | 178 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Dec 19, 2024 | clinicaltrials |
| NCT06742021 | Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer | recruiting | N/A | 195 | Yunnan Cancer HospitalOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT06705465 | Cross-sectorial Rehabilitation of Patients with Lung Cancer | recruiting | N/A | 130 | Camilla BalleOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06737107 | Multicenter Analysis of Different Approaches in Segmentectomies in Early-stage Lung Cancer(ANASEGME) | recruiting | — | 472 | Scientific Institute San RaffaeleOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT04170634 | Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT : the MEKANOS Study(MEKANOS) | recruiting | — | 220 | Hospices Civils de LyonOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06252233 | Improvement of Quality of Life (QoL) Using Preference-Oriented QoLMonitoring in Patients with Lung Cancer(LePaLuMo) | recruiting | N/A | 220 | University of BayreuthOTHER | 1 | Dec 16, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 29, 2025source: clinicaltrials